Welcome to our dedicated page for TruBridge SEC filings (Ticker: TBRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TruBridge, Inc. (NASDAQ: TBRG) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, drawn in real time from the EDGAR system and supported by AI-powered analysis. TruBridge is a healthcare technology and solutions company focused on rural and community hospitals and providers, and its filings offer detailed insight into how it reports financial performance, manages risk, and governs its operations.
Key documents for TruBridge include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company presents audited and interim financial statements, segment information for its Financial Health and Patient Care business units, and discussions of risk factors and internal control over financial reporting. For example, TruBridge has disclosed material weaknesses related to revenue processes and customer contract changes in prior years, and it has reported on changes to its independent registered public accounting firm, including the dismissal of Grant Thornton LLP and engagement of KPMG LLP.
Current reports on Form 8-K capture material events such as quarterly earnings releases, leadership changes, board refreshment actions, cooperation agreements with major shareholders, and financing developments like the 2025 Amended and Restated Credit Agreement with its lending partners. These filings help investors understand how TruBridge is addressing governance, capital structure, and strategic priorities in the context of rural and community healthcare.
On this page, users can review TruBridge’s Forms 10-K and 10-Q, 8-Ks describing significant corporate events, and other exhibits referenced in those reports. AI-generated summaries highlight the main points of each filing, explain complex accounting or control matters in plain language, and surface items related to revenue cycle management, EHR and patient engagement operations, internal control conclusions, and auditor changes. Filings related to executive and director arrangements, such as severance agreements and board appointments, are also accessible, along with any associated exhibits.
By using these tools, readers can quickly understand what TruBridge reports to regulators about its financial health, operational segments, governance, and risk profile, without having to parse every line of the underlying documents themselves.
Amendment No. 2 to a Schedule 13D for TruBridge, Inc. discloses that reporting persons Gran Fondo Capital B.V. and Rorema Beheer B.V. together beneficially own 950,158 shares, representing 6.3% of TruBridge's outstanding common stock based on 15,011,642 shares outstanding as of August 5, 2025. The filing states the shares were acquired for an aggregate purchase price of approximately $9,066,951, excluding commissions, using the reporting persons' working capital. This amendment is filed solely to include Schedule A, which was inadvertently omitted from Amendment No. 1; Schedule A contains transactions in the past 60 days. The issuer's principal executive office is listed in Mobile, Alabama.
Amendment No. 1 to a Schedule 13D reports that GRAN FONDO CAPITAL B.V. and Rorema Beheer B.V. together beneficially own 950,158 shares of TruBridge, Inc. common stock, representing 6.3% of the 15,011,642 shares outstanding referenced in the filing. The Reporting Persons say the shares were purchased for an aggregate price of approximately $9,066,951, paid from their working capital. The filing restates Item 3 (source and amount of funds) and Item 5 (interest in securities), references prior Schedule 13D dated June 10, 2024, and incorporates recent transactions on Schedule A. The filing identifies the issuer's principal executive office in Mobile, Alabama.
Insider sale disclosed: The filing shows that David Harse, listed as an officer with the title General Manager Patient Care, reported a sale of 1,744 shares of TruBridge, Inc. (TBRG) on 03/14/2025 at a reported price of $27.40 per share. After the transaction he beneficially owned 18,058 shares, held directly. The form is signed by an attorney by power of attorney on 08/15/2025. No derivative transactions or additional remarks are included in the filing.
TruBridge reported a quarter of positive operating results and improved profitability. Total revenues were $85.7 million for the three months ended June 30, 2025, essentially flat with the prior year period, while the company recorded GAAP net income of $2.58 million for the quarter and $3.04 million for the six months ended June 30, 2025, reversing prior-year losses. Adjusted EBITDA rose to $31.97 million for the six-month period from $23.77 million a year earlier, driven by expense reductions and higher recurring revenue.
The balance sheet shows $12.28 million in cash, total assets of $390.15 million and long-term debt (less current portion) of $163.11 million. Credit losses and financing receivables trends warrant attention: the allowance for credit losses increased to $0.82 million and total financing receivables declined to $2.75 million. The Patient Care reporting unit carries an accumulated goodwill impairment of $35.91 million, and the company is evaluating new tax legislation impacts.
Form 4 Overview: TruBridge, Inc. (TBRG) filed a Form 4 disclosing two routine transactions by President & CEO Christopher L. Fowler, who is also a director.
- July 1, 2024: 1,508 common shares were withheld by the company at $10.57 per share to satisfy tax obligations upon restricted-stock vesting (code “F”).
- July 1, 2025: 2,278 common shares were similarly withheld at $23.48 per share (code “F”).
Following the 2025 withholding, Fowler directly holds 127,304 common shares and indirectly holds 16 shares through his spouse, for a total of 127,320 shares.
Key Takeaways:
- The transactions are not open-market sales; they are non-discretionary tax withholdings, a common administrative action when restricted stock vests.
- No options or other derivative securities were reported.
- Fowler remains a significant insider with over 127k shares, indicating continued alignment with shareholder interests.